Latest headcount
15,410
YoY change
+2.0%
Headcount CAGR
+15.4%
Revenue / employee
$931K
Employee count history for Regeneron Pharmaceuticals
| Fiscal year | Employees |
|---|---|
| 1996 | 243 |
| 1997 | 270 |
| 1998 | 371 |
| 1999 | 437 |
| 2000 | 491 |
| 2001 | 575 |
| 2002 | 669 |
| 2003 | 644 |
| 2004 | 730 |
| 2005 | 230 |
| 2006 | 188 |
| 2007 | 682 |
| 2008 | 919 |
| 2009 | 1,029 |
| 2010 | 1,395 |
| 2011 | 1,704 |
| 2012 | 1,950 |
| 2013 | 2,340 |
| 2014 | 2,925 |
| 2015 | 4,300 |
| 2016 | 5,400 |
| 2017 | 6,200 |
| 2018 | 7,400 |
| 2019 | 8,100 |
| 2020 | 9,123 |
| 2021 | 10,368 |
| 2022 | 11,851 |
| 2023 | 13,450 |
| 2024 | 15,106 |
| 2025 | 15,410 |
Revenue per employee for Regeneron Pharmaceuticals
Annual revenue divided by reported headcount, normalized to US dollars.
| Fiscal year | Revenue per employee (USD) |
|---|---|
| 1996 | $99.2K |
| 1997 | $123K |
| 1998 | $103K |
| 1999 | $78.9K |
| 2000 | $121K |
| 2001 | $38.2K |
| 2002 | $32.9K |
| 2003 | $89.3K |
| 2004 | $238K |
| 2005 | $288K |
| 2006 | $337K |
| 2007 | $183K |
| 2008 | $259K |
| 2009 | $369K |
| 2010 | $329K |
| 2011 | $262K |
| 2012 | $707K |
| 2013 | $899K |
| 2014 | $964K |
| 2015 | $954K |
| 2016 | $900K |
| 2017 | $947K |
| 2018 | $907K |
| 2019 | $810K |
| 2020 | $931K |
| 2021 | $1.55M |
| 2022 | $1.03M |
| 2023 | $975K |
| 2024 | $940K |
| 2025 | $931K |
Earnings per employee for Regeneron Pharmaceuticals
Annual net income divided by reported headcount, normalized to US dollars; years with a net loss dip below zero.
| Fiscal year | Earnings per employee (USD) |
|---|---|
| 1996 | -$133K |
| 1997 | -$43K |
| 1998 | -$23.2K |
| 1999 | -$52.9K |
| 2000 | -$47.3K |
| 2001 | -$132K |
| 2002 | -$186K |
| 2003 | -$167K |
| 2004 | $57.1K |
| 2005 | -$415K |
| 2006 | -$544K |
| 2007 | -$155K |
| 2008 | -$90K |
| 2009 | -$65.9K |
| 2010 | -$74.9K |
| 2011 | -$130K |
| 2012 | $385K |
| 2013 | $181K |
| 2014 | $119K |
| 2015 | $148K |
| 2016 | $166K |
| 2017 | $193K |
| 2018 | $330K |
| 2019 | $261K |
| 2020 | $385K |
| 2021 | $779K |
| 2022 | $366K |
| 2023 | $294K |
| 2024 | $292K |
| 2025 | $292K |
Employee count history for Regeneron Pharmaceuticals (REGN)
Annual figures come from annual reports (10-K, or 20-F/40-F for foreign filers); interim rows reflect headcount disclosed in periodic filings. Year-over-year change compares each filing with the prior year's equivalent. Revenue and earnings per employee are annual figures normalized to US dollars.
- 202515,410+2.0%
- 202415,106+12.3%
- 202313,450+13.5%
- 202211,851+14.3%
- 202110,368+13.6%
- 20209,123+12.6%
- 20198,100+9.5%
- 20187,400+19.4%
- 20176,200+14.8%
- 20165,400+25.6%
- 20154,300+47.0%
- 20142,925+25.0%
- 20132,340+20.0%
- 20121,950+14.4%
- 20111,704+22.2%
- 20101,395+35.6%
- 20091,029+12.0%
- 2008919+34.8%
- 2007682+262.8%
- 2006188-18.3%
- 2005230-68.5%
- 2004730+13.4%
- 2003644-3.7%
- 2002669+16.3%
- 2001575+17.1%
- 2000491+12.4%
- 1999437+17.8%
- 1998371+37.4%
- 1997270+11.1%
- 1996243—
About Regeneron Pharmaceuticals's employee count
Regeneron Pharmaceuticals (REGN) employed 15,410 people in fiscal year 2025, based on its most recent annual report. That headcount grew by +304 (+2.0%) from 15,106 a year earlier.
Across the 1996–2025 period, the company's reported workforce went from 243 to 15,410 employees — a compound annual growth rate (CAGR) of +15.4% per year.
Regeneron Pharmaceuticals generated about $931K of revenue and $292K of net income per employee in its latest annual period. Revenue and earnings per employee gauge how efficiently a company turns headcount into output, and are most telling when tracked over time or compared with peers in the same industry.
Frequently asked questions
Test yourself on REGN
Employees — 10 rounds, every one of them REGN against another company. Leave whenever you like.
Practice run — it doesn’t move your skill rating and doesn’t touch the leaderboards. Misses do go into your review queue.
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.